Procter & Gamble Health
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Procter & Gamble Health Limited (PGHL) is navigating a complex landscape characterized by both growth opportunities and margin pressures. Management's recent commentary highlights a strategic pivot towards an 'Integrated Growth' strategy, focusing on the Vitamin, Mineral & Supplement (VMS) category, which is benefiting from increasing health consciousness and a structural shift towards preventive care in India. This focus on innovation and market expansion, including the addition of 50,000 new pharmacies and entry into underserved markets, supports Vista's revenue growth outlook, which anticipates a moderate increase driven by successful product launches and a growing export business. However, the company faces headwinds from rising input costs and softening urban consumer demand, which could pressure margins. Despite these challenges, the overall sentiment remains optimistic, with management emphasizing productivity initiatives to sustain margins. The Indian pharmaceutical B2C industry is expanding, providing a favorable backdrop for PGHL, although inflationary pressures and competitive dynamics warrant close monitoring. Over the next 12-24 months, key opportunities include leveraging new product innovations and expanding market reach, while watchpoints include input cost volatility and potential pricing power limitations
Why We Like This Stock
- Management's focus on the VMS category aligns with structural tailwinds in preventive healthcare, supporting revenue growth
- Successful product innovations and expansion into underserved markets enhance PGHL's competitive position
- The Indian pharmaceutical B2C industry's growth trajectory provides a favorable environment for PGHL's long-term prospects
Things To Watch Out For
- Rising input costs, particularly from crude-linked commodities, are expected to pressure margins
- Softening urban consumer demand may impact revenue growth in the near term
- Potential limitations on pricing power due to regulatory norms could affect profitability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,151 | 934 | 1,408 | 1,460 | 1,745 |
| Profit Before Tax (Cr.) | 294 | 312 | 450 | 503 | 590 |
| PBT Margin | 25.5% | 33.4% | 32.0% | 34.4% | 33.8% |
| Net Profit (Cr.) | 209 | 234 | 339 | 381 | 447 |
| Earnings Per Share | 126.0 | 140.7 | 204.3 | 229.3 | 269.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 7,535 | 27-May-2026 |
Company Overview
Show Company Profile
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.